The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
暂无分享,去创建一个
C. Cooper | N. Arden | C. Edwards | T. V. van Staa | M. Field | D. Fisher | C. Cooper
[1] T. Vogt,et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. , 2005, The Journal of rheumatology.
[2] C. Cooper,et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. , 2005, Rheumatology.
[3] M. Aringer,et al. Listeria-Associated Arthritis in a Patient Undergoing Etanercept Therapy: Case Report and Review of the Literature , 2005, Journal of Clinical Microbiology.
[4] S. Tsiodras,et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use , 2005, Scandinavian journal of infectious diseases.
[5] K. Nadarajah,et al. Listeria monocytogenes septic arthritis in a patient treated with etanercept for rheumatoid arthritis. , 2005, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[6] S. Rachapalli,et al. Septic arthritis due to Listeria monocytogenes in a patient receiving etanercept. , 2005, Arthritis and rheumatism.
[7] F. Strle,et al. Comparison of patients fulfilling criteria for confirmed and probable human granulocytic ehrlichiosis , 2004, Scandinavian journal of infectious diseases.
[8] D. Isenberg,et al. Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy , 2004, The Journal of experimental medicine.
[9] R. DeHoratius,et al. Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy. , 2004, The Journal of rheumatology.
[10] Ehrenstein,et al. Compromised function of regulatory T cells in rheumatoid arthritis: Reversal by anti-TNF alpha therapy , 2004 .
[11] C. Cooper,et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with RA from the general practice research database (GPRD). , 2004 .
[12] I. Olivieri,et al. Septic arthritis caused by Moraxella catarrhalis associated with infliximab treatment in a patient with undifferentiated spondarthritis , 2003, Annals of the Rheumatic Diseases.
[13] H. Amital,et al. Bilateral septic arthritis of the hip: does etanercept play a role? A case report. , 2003, The Journal of bone and joint surgery. American volume.
[14] H. Chng,et al. Five‐and‐a‐half year study of 107 patients with septic arthritis in a general hospital in Singapore , 2003 .
[15] Robert L Elwood,et al. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. , 2003, The Pediatric infectious disease journal.
[16] W. Bilker,et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease , 2002, Pharmacoepidemiology and drug safety.
[17] E. Matteson,et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. , 2001, Mayo Clinic proceedings.
[18] R. Sturrock,et al. A prospective 2-year study of 75 patients with adult-onset septic arthritis. , 2001, Rheumatology.
[19] C. Cooper,et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. , 2000, Rheumatology.
[20] M. Suarez‐Almazor,et al. Cyclophosphamide for treating rheumatoid arthritis. , 2000, The Cochrane database of systematic reviews.
[21] L Abenhaim,et al. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results , 2000, Pharmacoepidemiology and drug safety.
[22] L. V. D. van de Putte,et al. Septic arthritis with Listeria monocytogenes during low‐dose methotrexate , 1998, Journal of internal medicine.
[23] T. Walley,et al. The UK General Practice Research Database , 1997, The Lancet.
[24] B. Dijkmans,et al. Incidence and sources of native and prosthetic joint infection: a community based prospective survey , 1997, Annals of the rheumatic diseases.
[25] J. Habbema,et al. The outcome of bacterial arthritis: a prospective community-based study. , 1997, Arthritis & Rheumatism.
[26] B. Hazleman,et al. Bacterial joint infections in England and Wales: analysis of bacterial isolates over a four year period. , 1997, British Journal of Rheumatology.
[27] J. Habbema,et al. Risk factors for septic arthritis in patients with joint disease. A prospective study. , 1995, Arthritis and rheumatism.
[28] M. Gari-Toussaint,et al. Fatal outcome of Aspergillus fumigatus arthritis in a renal transplant recipient. , 1995, Transplantation proceedings.
[29] R. Mann,et al. The VAMP Research multi-purpose database in the U.K. , 1995, Journal of clinical epidemiology.
[30] G. Hall. Pharmacoepidemiology using a UK database of primary care records , 1992 .
[31] M. Cawley,et al. Bacterial arthritis in an English health district: a 10 year review. , 1986, Annals of the rheumatic diseases.